Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 7Active not recruiting 3Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 6Breast Neoplasms 5Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Glioma 3Solid Tumors 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Melanoma 2Brain Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Papillomavirus Infections 1Pancreatic Ductal Adenocarcinoma 1PTEN Gene Mutation 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neuroma 1

Interventions

Monatide (IMS 3015) 1Biological Assay 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasm, Residual × 30 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡